119 related articles for article (PubMed ID: 12646571)
1. A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy.
Wu SC; Castellino FJ; Wong SL
J Biol Chem; 2003 May; 278(20):18199-206. PubMed ID: 12646571
[TBL] [Abstract][Full Text] [Related]
2. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
3. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin.
Sakharov DV; Lijnen HR; Rijken DC
J Biol Chem; 1996 Nov; 271(44):27912-8. PubMed ID: 8910391
[TBL] [Abstract][Full Text] [Related]
4. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
Lian Q; Szarka SJ; Ng KK; Wong SL
J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the interaction between plasminogen and staphylokinase.
Lijnen HR; De Cock F; Van Hoef B; Schlott B; Collen D
Eur J Biochem; 1994 Aug; 224(1):143-9. PubMed ID: 8076635
[TBL] [Abstract][Full Text] [Related]
6. On the mechanism of fibrin-specific plasminogen activation by staphylokinase.
Lijnen HR; Van Hoef B; De Cock F; Okada K; Ueshima S; Matsuo O; Collen D
J Biol Chem; 1991 Jun; 266(18):11826-32. PubMed ID: 2050679
[TBL] [Abstract][Full Text] [Related]
7. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
[TBL] [Abstract][Full Text] [Related]
8. On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
Lijnen HR; Van Hoef B; Matsuo O; Collen D
Biochim Biophys Acta; 1992 Jan; 1118(2):144-8. PubMed ID: 1730031
[TBL] [Abstract][Full Text] [Related]
9. Design of a thrombin inhibitory staphylokinase based plasminogen activator with anti-reocclusion potential.
Arora K; Maheshwari N; Sahni G
Int J Biol Macromol; 2020 Feb; 144():791-800. PubMed ID: 31739007
[TBL] [Abstract][Full Text] [Related]
10. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
[TBL] [Abstract][Full Text] [Related]
13. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
14. Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Szarka SJ; Sihota EG; Habibi HR; Wong S
Appl Environ Microbiol; 1999 Feb; 65(2):506-13. PubMed ID: 9925575
[TBL] [Abstract][Full Text] [Related]
15. Designing a multifunctional staphylokinase variant (SAK-2RGD-TTI) with appropriate thrombolytic activity in vitro.
Faraji H; Soltani F; Ramezani M; Sadeghnia HR; Nedaeinia R; Moghimi Benhangi H; Mashkani B
Biotechnol Lett; 2020 Jan; 42(1):103-114. PubMed ID: 31686286
[TBL] [Abstract][Full Text] [Related]
16. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
17. Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA).
Rijken DC; Barrett-Bergshoeff MM; Jie AF; Criscuoli M; Sakharov DV
Thromb Haemost; 2004 Jan; 91(1):52-60. PubMed ID: 14691568
[TBL] [Abstract][Full Text] [Related]
18. Integration of VEK-30 peptide enhances fibrinolytic properties of staphylokinase.
Bhando T; Singh S; Hade MD; Kaur J; Dikshit KL
Biotechnol Appl Biochem; 2021 Apr; 68(2):213-220. PubMed ID: 32233032
[TBL] [Abstract][Full Text] [Related]
19. Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris.
Vandana ; Kantipudi S; Maheshwari N; Sharma S; Sahni G
Protein Expr Purif; 2019 Oct; 162():1-8. PubMed ID: 31108209
[TBL] [Abstract][Full Text] [Related]
20. Interaction of staphylokinase with different molecular forms of plasminogen.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1993 Jan; 211(1-2):91-7. PubMed ID: 8425556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
